These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28475601)

  • 1. High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.
    Honda H; Michihata T; Shishido K; Takahashi K; Takahashi G; Hosaka N; Ikeda M; Sanada D; Shibata T
    PLoS One; 2017; 12(5):e0176984. PubMed ID: 28475601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study.
    Lewerin C; Ljunggren Ö; Nilsson-Ehle H; Karlsson MK; Herlitz H; Lorentzon M; Ohlsson C; Mellström D
    Bone; 2017 May; 98():1-8. PubMed ID: 28212898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.
    Wan L; Zhang D
    Int Urol Nephrol; 2018 Aug; 50(8):1511-1518. PubMed ID: 29946818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Robinson BM; Larkina M; Bieber B; Kleophas W; Li Y; Locatelli F; McCullough KP; Nolen JG; Port FK; Pisoni RL
    BMC Nephrol; 2017 Nov; 18(1):330. PubMed ID: 29121874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
    Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
    Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron indices and intravenous ferumoxytol: time to steady-state.
    Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J
    Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
    Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.
    Honda H; Tanaka K; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
    Blood Purif; 2019; 47 Suppl 2():63-69. PubMed ID: 30943476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis.
    Honda H; Tanaka K; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Ganz T; Higashimoto Y
    Clin Kidney J; 2021 Mar; 14(3):943-949. PubMed ID: 33777378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
    Li H; Wang SX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Effects of Iron Indices on Mortality in Patients With Autosomal Dominant Polycystic Kidney Disease After Long-Term Hemodialysis: A Nationwide Population-Based Study.
    Yeh SC; Lin YC; Hong YC; Hsu CC; Lin YC; Wu MS
    J Ren Nutr; 2019 Sep; 29(5):444-453. PubMed ID: 30683605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth-factor 23 and vitamin D are associated with iron deficiency and anemia in children with chronic kidney disease.
    Karava V; Dotis J; Kondou A; Christoforidis A; Taparkou A; Farmaki E; Economou M; Printza N
    Pediatr Nephrol; 2023 Aug; 38(8):2771-2779. PubMed ID: 36862253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.